{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T06:12:12Z","timestamp":1759385532075},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.diabet.2008.05.009","type":"journal-article","created":{"date-parts":[[2008,10,16]],"date-time":"2008-10-16T09:37:53Z","timestamp":1224149873000},"page":"587-594","source":"Crossref","is-referenced-by-count":20,"title":["Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy"],"prefix":"10.1016","volume":"34","author":[{"given":"M.","family":"Cocchietto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Zorzin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Toffoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Candido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Stebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Sava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2008.05.009_bib1","first-page":"49","article-title":"Glycation and complication of diabetes","volume":"30","author":"Turk","year":"2001","journal-title":"Diabetologia Croat"},{"key":"10.1016\/j.diabet.2008.05.009_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/bmj.325.7355.59","article-title":"Diabetic nephropathy","volume":"325","author":"Harvey","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2008.05.009_bib3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.CIR.0000021122.63813.32","article-title":"Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice","volume":"106","author":"Candido","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2008.05.009_bib4","first-page":"40","article-title":"Identifying and managing the complications of diabetes","volume":"100","author":"Hill","year":"2004","journal-title":"Nurs Times"},{"key":"10.1016\/j.diabet.2008.05.009_bib5","first-page":"385","article-title":"Diabetic nephropathy: implications for renal and cardiovascular outcomes","volume":"95","author":"Folan","year":"2004","journal-title":"Minerva Med"},{"key":"10.1016\/j.diabet.2008.05.009_bib6","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/01.mjt.0000178769.52610.69","article-title":"Advanced glycation end products and diabetic nephropathy","volume":"12","author":"Thomas","year":"2005","journal-title":"Am J Ther"},{"key":"10.1016\/j.diabet.2008.05.009_bib7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2008.05.009_bib8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2008.05.009_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/07853899608999102","article-title":"Advanced glycation end products and atherosclerosis","volume":"28","author":"Vlassara","year":"1996","journal-title":"Ann Med"},{"key":"10.1016\/j.diabet.2008.05.009_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1358836X9800300207","article-title":"Diabetes, advanced glycation end products and vascular disease","volume":"3","author":"Wautier","year":"1998","journal-title":"Vasc Med"},{"key":"10.1016\/j.diabet.2008.05.009_bib11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.7326\/0003-4819-101-4-527","article-title":"Nonenzymatic glycation and the pathogenesis of diabetic complications","volume":"101","author":"Brownlee","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2008.05.009_bib12","first-page":"92","article-title":"Nonenzymatic glycosylation and chronic complications of diabetes: an overview","volume":"27","author":"Kennedy","year":"1984","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2008.05.009_bib13","doi-asserted-by":"crossref","first-page":"11704","DOI":"10.1073\/pnas.91.24.11704","article-title":"Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats","volume":"91","author":"Vlassara","year":"1994","journal-title":"Proc Natl Aca Sci U S A"},{"key":"10.1016\/j.diabet.2008.05.009_bib14","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.micinf.2004.08.004","article-title":"RAGE (receptor for advanced glycation end products): a central player in the inflammatory response","volume":"6","author":"Chavakis","year":"2004","journal-title":"Microbes Infect"},{"key":"10.1016\/j.diabet.2008.05.009_bib15","first-page":"535","article-title":"Advanced glycation end products, their receptors and diabetic angiopathy","volume":"27","author":"Wautier","year":"2001","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2008.05.009_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2796.2002.00932.x","article-title":"Diabetes and advanced glycation end products","volume":"251","author":"Vlassara","year":"2002","journal-title":"Intern Med J"},{"key":"10.1016\/j.diabet.2008.05.009_bib17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.cardiores.2004.05.001","article-title":"Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes","volume":"63","author":"Basta","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.diabet.2008.05.009_bib18","series-title":"Posttranslational modification of proteins","first-page":"53","article-title":"Advanced glycosylation end products","author":"Bucala","year":"1992"},{"key":"10.1016\/j.diabet.2008.05.009_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1172\/JCI117307","article-title":"AGEing growth factors: a role in diabetic vascular disease?","volume":"94","author":"Baynes","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2008.05.009_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cyto.2004.06.006","article-title":"Advanced glycation end products upregulate angiogenic and proinflammatory cytokine production in human monocyte\/macrophages","volume":"28","author":"Pertynska-Marczewska","year":"2004","journal-title":"Cytokine"},{"key":"10.1016\/j.diabet.2008.05.009_bib21","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2337\/diabetes.52.6.1441","article-title":"Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice","volume":"52","author":"Peppa","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2008.05.009_bib22","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.4049\/jimmunol.173.2.1399","article-title":"Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products","volume":"173","author":"Chen","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.diabet.2008.05.009_bib23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.neurobiolaging.2003.11.001","article-title":"Autoimmunity in Alzheimer\u2019s disease: increased levels of circulating IgG binding Abeta and RAGE peptides","volume":"25","author":"Mruthinti","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.diabet.2008.05.009_bib24","series-title":"Lysozyme: Model enzymes in biochemistry and biology","first-page":"433","article-title":"Pharmacological aspects and therapeutic applications of lysozymes","author":"Sava","year":"1996"},{"key":"10.1016\/j.diabet.2008.05.009_bib25","first-page":"275","article-title":"A possible physiological function of lysozyme","volume":"25","author":"Joll\u00e8s","year":"1976","journal-title":"Biomedicine"},{"key":"10.1016\/j.diabet.2008.05.009_bib26","first-page":"145","article-title":"Cytofluorimetric analysis of gut-intraepithelial and mesenteric lymph node lymphocytes of tumour-bearing mice fed with egg-white lysozyme","volume":"16","author":"Pacor","year":"1996","journal-title":"Anticancer Res"},{"key":"10.1016\/j.diabet.2008.05.009_bib27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1773-2247(06)50081-4","article-title":"Lysozyme-containing chitosan-coated alginate microspheres for oral immunisation","volume":"16","author":"Zorzin","year":"2006","journal-title":"J Drug Del Sci Tech"},{"key":"10.1016\/j.diabet.2008.05.009_bib28","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1073\/pnas.81.8.2489","article-title":"Processing of lysozyme by macrophages: identification of the determinant recognized by two T-cell hybridomas","volume":"81","author":"Allen","year":"1984","journal-title":"Proc Nat Acad Sci U S A"},{"key":"10.1016\/j.diabet.2008.05.009_bib29","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1172\/JCI119600","article-title":"Depletion of reactive advanced glycation end products from diabetic uremic sera using a lysozyme-linked matrix","volume":"100","author":"Mitsuhashi","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2008.05.009_bib30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/BF03401963","article-title":"Lysozyme enhances renal excretion of advanced glycation end products in vivo and suppresses adverse age-mediated cellular effects in vitro: a potential age sequestration therapy for diabetic nephropathy?","volume":"7","author":"Zheng","year":"2001","journal-title":"Mol Med"},{"key":"10.1016\/j.diabet.2008.05.009_bib31","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/nm1095-1057","article-title":"Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif","volume":"1","author":"Li","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.diabet.2008.05.009_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0168-3659(03)00194-9","article-title":"Biodegradable microcapsules for protein delivery","volume":"90","author":"Sihna","year":"2003","journal-title":"J Control Release"},{"key":"10.1016\/j.diabet.2008.05.009_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0378-5173(03)00087-5","article-title":"Bioadhesive microcapsules as a controlled drug delivery system","volume":"255","author":"Vasir","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1016\/j.diabet.2008.05.009_bib34","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.2337\/diabetes.51.11.3274","article-title":"Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy","volume":"51","author":"Forbes","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2008.05.009_bib35","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1016\/S0021-9258(18)42741-X","article-title":"Immunochemical detection of advanced glycosylation end products in vivo","volume":"267","author":"Makita","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diabet.2008.05.009_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0168-3659(90)90133-E","article-title":"Controlled vaccine release in the gut-associated lymphoid tissue. I. Orally administered biodegradable microspheres target the Peyer\u2019s patches","volume":"11","author":"Eldridge","year":"1990","journal-title":"J Control Release"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363608001912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363608001912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T21:49:42Z","timestamp":1632001782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363608001912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S1262363608001912"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2008.05.009","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}